The Role of Homocysteine in End‐Stage Renal Disease

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Seminars in Dialysis

• Publication date

  1998-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1525-139X.1998.tb00309.x
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Excerpts From the United States Renal Data System 2002 Annual Data Report

  2003cited by this paper
• Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia.

  1997cited by this paper
• The vascular dementia of Fabry's disease.

  1997cited by this paper
• Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.

  1997cited by this paper
• Regional brain distribution and binding of the muscarinic receptor agonist CI-979 studied by positron emission tomography in the monkey.

  1997cited by this paper
• Subpial amyloid plaques in the cerebellum in a case of Alzheimer's disease.

  1997cited by this paper
• Homocysteine and coronary artery disease.

  1997cited by this paper
• Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes.

  1997cited by this paper
• Homocysteine and folate concentrations in blood from patients treated with hemodialysis.

  1996cited by this paper
• Folic acid treatment of hyperhomocysteinemia in dialysis patients.

  1996cited by this paper
• High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients.

  1996cited by this paper
• Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits.

  1996cited by this paper
• Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease.

  1996cited by this paper
• Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients.

  1996cited by this paper
• Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.

  1996cited by this paper
• Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients.

  1996cited by this paper
• Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations.

  1996cited by this paper
• A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

  1995cited by this paper
• Net uptake of plasma homocysteine by the rat kidney in vivo.

  1995cited by this paper
• Beta-amyloid deposition in the medial temporal lobe in elderly non-demented brains and in Alzheimer's disease.

  1995cited by this paper
• Serum total homocysteine and coronary heart disease.

  1995cited by this paper
• A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

  1995cited by this paper
• Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.

  1995cited by this paper
• Hyperhomocysteinaemia: a role in the accelerated atherogenesis of chronic renal failure?

  1995cited by this paper
• Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis.

  1995cited by this paper
• Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure.

  1995cited by this paper
• Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients.

  1995cited by this paper
• Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation.

  1995cited by this paper
• Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients.

  1994cited by this paper
• Importance of elevated plasma homocysteine levels as a risk factor for atherosclerosis.

  1994cited by this paper
• Withdrawal of folic acid supplementation in maintenance hemodialysis patients.

  1994cited by this paper
• Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients.

  1994cited by this paper
• Vitamin status and intake as primary determinants of homocysteinemia in an elderly population.

  1993cited by this paper
• Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients.

  1993cited by this paper
• Plasma homocysteine in renal failure.

  1993cited by this paper
• The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients.

  1993cited by this paper
• The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine.

  1992cited by this paper
• A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians.

  1992cited by this paper
• Hyperhomocysteinemia: an independent risk factor for vascular disease.

  1991cited by this paper
• Risk factors for stroke in middle aged British men.

  1991cited by this paper
• Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease.

  1991cited by this paper
• Concentrations of total homocysteine in plasma in chronic renal failure.

  1990cited by this paper
• Disorders of transsulfuration

  1989cited by this paper
• Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease.

  1988cited by this paper
• Altered plasma free and protein-bound sulfur amino acid levels in patients undergoing maintenance hemodialysis.

  1987cited by this paper
• Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease.

  1985cited by this paper
• Plasma protein-bound homocyst(e)ine in patients requiring chronic haemodialysis.

  1983cited by this paper
• Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis.

  1980cited by this paper
• Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine‐homocysteine mixed disulphide

  1979cited by this paper

• A multi-responsive coumarin–benzothiazole fluorescent probe for selective detection of biological thiols and hydrazine

  2021cites this paper
• Principles of Hemodialysis

  2019cites this paper
• Chapter 20 – Principles of Hemodialysis

  2010cites this paper
• Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients

  2005cites this paper
• Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease.

  2002cites this paper
• Post-methionine-load hyperhomocysteinemia and increased lipoprotein(a) are associated with renal metabolic dysfunction: a hypothesis.

  2002cites this paper
• Polymorphism in Methylenetetrahydrofolate Reductase Gene: Its Impact on Plasma Homocysteine Levels and Carotid Atherosclerosis in ESRD Patients Receiving Hemodialysis

  2001cites this paper
• Parenteral vitamin B12 reduces hyperhomocysteinemia in end-stage renal disease.

  2001cites this paper
• The Importance of Hyperhomocysteinemia as a Risk Factor for Diseases: An Overview

  2001cites this paper
• C-Reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD

  2000cites this paper
• A tale of two homocysteines--and two hemodialysis units.

  2000cites this paper
• Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients.

  1999cites this paper